In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Supporting investigators and sites in the evolution to decentralised clinical trials
In this article from International Biopharmaceutical Industry, Harpreet Gill, Vice President of Real-World Solutions - Project Management reflects on how investigators and sites can be supported and partnered as the use of decentralised clinical trials evolves.
-
Diabesity: Implications for treatment and drug development
In this Journal for Clinical Studies’ article, Simon Bruce and Jack Martin discuss the overlap in pathophysiology and treatment of diabetes and obesity along with considerations for streamlining the clinical development of treatments that have therapeutic promise for both conditions.
-
ICON announces results from survey on obesity-related clinical research
This news article, from Applied Clinical Trials, outlines findings from ICON’s recent survey of over 100 industry professionals on their opinions on future research within the therapeutic area of obesity treatment.
-
ICON survey stresses combo therapies in obesity care
This news piece from The Clinical Trial Vanguard provides an overview of the findings from ICON’s recent survey of professionals engaged in obesity-related clinical research. It outlines that most respondents believe that obesity therapy trials should measure multiple outcomes due to the overlap between obesity and related comorbidities.
-
Turning clinical research into virtual capacity
In this article in The Journal of mHealth, Madelaine MacKay, Senior Director, Product Management outlines that to keep patients and care provider needs at the core, four elements should be considered when adopting modern clinical trial approaches: flexibility, consistency, creativity, simplicity.
-
ICON predicts biotech trial demand will grow despite economic pressures
This article from Clinical Insider outlines ICON’s view that the demand for clinical trial services will increase in 2024, in addition to providing an overview of the results of the recent ICON biotech sector survey, the findings of which suggest that biotech R&D spending is likely to increase.
-
From Vaccines to Oncology and Beyond: Tracking mRNA’s Progress
In this article, ICON’s Andreas Dreps and Martin Lachs discuss how the success of mRNA-based vaccines paves the way for mRNA in oncology and beyond.
-
Practical considerations for managing cell and gene therapy supply chains
In this article in Clinical Research News, Alyssa Gilliam, Vice President, CSM & IRT and Chad Crafford, Clinical Supplies Manager outline practical considerations for managing your CGT supply chain to minimise risk, mitigate cost and complexity.
-
48% of biotechs leaning on Big Pharma as current funding method: ICON survey
This article from Fierce Biotech provides an overview of findings from the ICON 2023 biotech sector survey, which shows that despite cash struggles, 60% of the survey respondents anticipate their R&D spend to rise over the next one to two years.
-
IMI Mobilise-D: The next generation of mobility research
In this article from International Pharmaceutical Industry, Gerard Quinn, VP, IT Innovation and Informatics, provides an overview on the Innovative Medicines Initiative (IMI) funded Mobilise-D project, which aims to develop a comprehensive system to analyse people’s gait using digital technologies, including sponsors worn on the body.
